Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506969 | 0.93 | ALDH1A1 (0.50) | L3MBTL1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL4424935 | 0.91 | PDK1 (0.43) | L3MBTL1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL4415858 | 0.91 | FAAH (0.42) | L3MBTL1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL4415239 | 0.89 | SMN1; SMN2 (0.46) | L3MBTL1KDM4EMAPTALDH2 | |
| SCHEMBL4412123 | 0.88 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1GAAMAPTS1PR1 | |
| SCHEMBL4418914 | 0.87 | ALDH1A1 (0.45) | L3MBTL1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL4422665 | 0.87 | GAA (0.39) | L3MBTL1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL4415737 | 0.87 | P2RX3 (0.39) | L3MBTL1KDM4EALDH1A1GAAALDH2 | |
| SCHEMBL2179233 | 0.87 | MAOB (0.41) | L3MBTL1GAAMAPTS1PR1ALDH2 | |
| SCHEMBL2170676 | 0.86 | LMNA (0.44) | L3MBTL1ALDH1A1GAAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | claimed |
| EP-1680124-A4 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2009-05-13 | — | — | EP | claimed |
| JP-2007508374-A | — | — | 2007-04-05 | — | — | JP | claimed |
| EP-1680124-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | Pfizer Products Incorporated (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | claimed |
| WO-2005037216-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-7473787-B2 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC (US) | 2009-01-06 | — | — | US | disclosed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | SLC6A5, SLC1A5, SLC6A3 | L3MBTL1 1416/4885KDM4E 2032/4885ALDH1A1 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.